UNSPSC 51271501: Chlorobutanol

This classification denotes an industrial aid with the molecular formula C4H7Cl3O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier HM4YQM8WRC, chemically known as 1,1,1-trichloro-tert-butyl alcohol but generally known as chlorobutanol, which bears US NIH Compound Identifier 5977. European Medicines Agency schedules Chlorobutanol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06190MIG.

UNSPSC 51271501 Chlorobutanol is a Commodity code under which state and local governments procure pharmaceutical preservatives and chemical additives used in medicinal formulations, drug manufacturing compliance, and hospital pharmacy operations. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) administered by the Minnesota Department of Administration's Office of State Procurement recently issued an RFP on January 20, 2026 to establish multiple contracts for generic multi-source pharmaceuticals and over-the-counter products distributed across participating state and local government facilities in Minnesota and Oregon. The scope encompasses manufacturers supplying comprehensive pharmaceutical product lines with specific National Drug Codes (NDC), including detailed product information, SKUs, UPCs, generic descriptions, strength, dosage forms, trade names, packaging configurations, and manufacturing locations. Vendors must certify compliance with current Good Manufacturing Practices (cGMP) and the Drug Supply Chain Security Act (DSCSA), maintain contractual relationships with at least two of three authorized wholesalers (AmerisourceBergen Drug Corporation, Cardinal Health, and Morris & Dickson Co., LLC) with chargeback systems in place, and demonstrate pricing flexibility through flat price, net price formats, or WAC-minus structures. All products must be available in the marketplace by May 15, 2026, with contract effectiveness set for July 1, 2026. The RFP does not identify set-aside restrictions or particular business-classification limitations based on available documentation.

The MMCAP solicitation represents a multistate cooperative purchasing vehicle spanning Minnesota and Oregon with two-year contract terms and optional extensions through June 30, 2028. Evaluation is weighted heavily on price competitiveness (75 percent), with secondary consideration for fixed pricing (10 percent), administrative fee format compliance (5 percent), EDI capability (5 percent), and agreement to a 3 percent administrative fee (5 percent). Vendors must maintain comprehensive insurance coverage including commercial general liability of $5,000,000 per occurrence, network security and privacy liability of $2,000,000, and professional liability of $2,000,000. The due date for proposals was March 26, 2026, with a cutoff date for questions on February 18, 2026. Specific award values or budget ranges are not disclosed; vendors should anticipate performance penalties ranging from $200 to $1,500 per violation for late reporting, missed onboarding timelines, or improper class-of-trade denials. MMCAP reserves the right to make sole awards, dual awards, or multi-awards based on therapeutic considerations, product availability, patient safety, and member-specific needs.